Podcasts

Dr Dietrich discusses the rationale for testing for HER2 and MET mutations in patients with NSCLC, as well as best practices for implementing this testing.

Connie Lai, MD, discusses a retrospective, dual-center study examining post-induction treatment strategies in metastatic colorectal cancer.

Read a recap of the episodes of OncLive On Air that debuted in June 2025.

Chandler Park, MD and Midhun Malla, MD discuss treatment personalization in mCRC, with a focus on BRAF V600E–mutant tumors and HER2-altered disease.

Drs Armstrong and Tawagi discuss key efficacy, safety, and patient-reported outcomes from the phase 3 SERENA-6 study.

Park and Malla discuss evolving approaches to colorectal cancer (CRC) management, with a focus on ctDNA, adjuvant therapy decision-making, and molecular profiling in metastatic disease.

Drs Park and Hanona discuss the ways that public health content creation offers practical advice about a variety of topics but may also spark debate.

In this episode, Drs Park and Hanona give advice to up-and-coming oncology content creators.

Drs Park and Hanona discuss the role of social media in educating patients and oncologists about treatment advances and novel cancer screening methods.

Nataliya Uboha, MD, PhD, discusses the FDA approval of first-line tislelizumab-jsgr with platinum-containing chemotherapy for unresectable or metastatic ESCC.

Virginia Kaklamani, MD, DSc, discusses the mechanism of action of inavolisib and the importance of the addition of this agent to the HR-positive metastatic breast cancer treatment paradigm.

Dr Tap discusses the significance of this approval, key efficacy and safety data from the phase 3 MOTION trial, and the important role that multidisciplinary collaboration will play in integrating this therapy into clinical practice.

Marwan G. Fakih, MD discusses the significance of this approval, key findings from the pivotal CodeBreaK 300 trial, and how this combination fits into the current KRAS G12C–mutated mCRC treatment paradigm.

Christopher L. Moertel, MD, discusses the significance of the FDA approval of mirdametinib, based on efficacy and safety data from the phase 2 ReNeu trial.

Dr Bardia discusses the significance of the FDA approval of Dato-DXd, and pivotal findings from the phase 3 TROPION-Breast01 trial that led to the approval.

Dr Gerber discusses the evolving role of ADCs in NSCLC, focusing on findings from clinical trials and considerations regarding the toxicity profile of TROP2-directed ADCs.

Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.

Dr Moreau highlights key findings on MRD negativity dynamics from IMROZ and their future implications for patients with newly diagnosed multiple myeloma.

Drs Camidge and Redman discuss Dr Redman's role as a biostatistician at Fred Hutch, outlining her work in designing clinical trials.

Andre Goy, MD, discusses top hematologic oncology research from the 2024 ASH Annual Meeting.

Sagar D. Sardesai, MBBS, discusses the phase 3 ELAINE-3 trial evaluating lasofoxifene plus abemaciclib in ESR1-mutant, ER+/HER2- metastatic breast cancer.

Hear Chandler Park, MD and Stephen Liu, MD, explore advancements in EGFR-mutated NSCLC treatment, including TKI strategies, emerging therapies prioritizing a patient-centric approach.

Dr Campos discusses clinical implications from the gynecologic cancer cohorts of DESTINY-PanTumor02 and considerations for managing adverse effects in patients receiving T-DXd.

Dr Ajani discusses the FDA approval of frontline zolbetuximab plus chemo for unresectable or metastatic, HER2–, CLDN18.2+ gastric or GEJ adenocarcinoma.

Kevin Kalinsky, MD, MS, discusses his top takeaways from the 2024 ASCO Annual Meeting and 2024 ESMO Congress, as well as where he sees the field of breast cancer evolving into the future.

In this Oncology Unplugged episode, Dr. Chandler Park and Dr. Vivek Subbiah discuss advancements in precision oncology, next-gen sequencing, and tissue-agnostic therapies.

Hear Alan P. Venook, MD, discuss recent updates to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for gastrointestinal cancers.

Drs Park and Patil delve into the evolving SCLC treatment paradigm by examining data from recent studies and focus on treatment developments for patients with ALK-positive NSCLC.